Boundless Bio to Present at 2024 Citizens JMP Life Sciences Conference

Boundless Bio, a clinical-stage oncology firm listed on Nasdaq as BOLD, is pioneering innovative cancer treatments by exploring extrachromosomal DNA (ecDNA) biology. The company has announced that its Chief Financial Officer, Jami Rubin, will be presenting at the Citizens JMP Life Sciences Conference 2024. This presentation will take place on Monday, May 13, at 1:00 p.m. ET in New York, NY. Those interested can access the live and archived webcast of the presentation through the "Events & Presentations" section on the Investors page of Boundless Bio's website.

Boundless Bio is committed to addressing the critical needs of patients suffering from oncogene amplified cancers, which affect over 14% of cancer patients. The company’s strategy revolves around targeting ecDNA, which plays a crucial role in oncogene amplification. One of the groundbreaking therapies being developed by Boundless Bio is BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1). This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy in patients with oncogene amplified cancers.

Another promising candidate in Boundless Bio’s pipeline is BBI-825, an oral inhibitor of ribonucleotide reductase (RNR). This drug is also in Phase 1/2 clinical trials and is being tested in cancer patients who have resistance gene amplifications. These trials are critical steps in determining the potential of these therapies to offer new hope to patients for whom existing treatments have been ineffective.

Boundless Bio leverages its proprietary Spyglass platform to drive the development of these therapies. The platform aids in the discovery and preclinical development of additional programs that are aimed at further transforming the landscape of cancer treatment. Headquartered in San Diego, CA, Boundless Bio continues to push the boundaries of oncology research and development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!